{
  "retracted": false,
  "timestamp": 1584662400000,
  "updates": [
    {
      "timestamp": 1587307242556,
      "identifier": {
        "doi": "10.1016/j.jpba.2019.04.047"
      },
      "type": "erratum"
    }
  ],
  "identifier": {
    "doi": "10.1016/j.jpba.2018.12.038"
  },
  "journal": "Journal of Pharmaceutical and Biomedical Analysis",
  "publisher": "Elsevier BV",
  "title": "Corrigendum to “A high-performance liquid chromatography-tandem mass spectrometry method for the analysis of lifirafenib, a novel RAF kinase and EGFR inhibitor, in human plasma and urine, and its application in a clinical pharmacokinetic study” [J. Pharm. Biomed. Anal. 166 (2019) 20–29]"
}
